Abstract
Mycoplasma pneumoniae is an important pathogen of the upper and lower respiratory tracts of children and adults. Historically, it has been susceptible in vitro to macrolides, tetracyclines, and fluoroquinolones. Standardized methods for performance and interpretation of in vitro susceptibility tests have now been published for M. pneumoniae and mechanisms of acquired resistance to macrolides have been shown to be due to mutations in the 23S rRNA gene. Emergence and widespread dissemination of clinically significant high-level macrolide resistance in Asia and documentation of its occurrence to a lesser extent in several European countries and the United States during the past decade is worrisome since treatment options for children are limited. This article summarizes the current status of antimicrobial susceptibility testing, mechanisms of antimicrobial resistance, epidemiology of macrolide resistance and treatment alternatives for pediatric infections caused by M. pneumoniae.
Keywords: Mycoplasma pneumoniae, antimicrobial susceptibility, treatment, antibiotic resistance, macrolide.
Current Pediatric Reviews
Title:Antimicrobial Susceptibilities and Treatment Options for Pediatric Mycoplasma pneumoniae Infections - Does Macrolide Resistance Matter?
Volume: 9 Issue: 4
Author(s): Ken B. Waites
Affiliation:
Keywords: Mycoplasma pneumoniae, antimicrobial susceptibility, treatment, antibiotic resistance, macrolide.
Abstract: Mycoplasma pneumoniae is an important pathogen of the upper and lower respiratory tracts of children and adults. Historically, it has been susceptible in vitro to macrolides, tetracyclines, and fluoroquinolones. Standardized methods for performance and interpretation of in vitro susceptibility tests have now been published for M. pneumoniae and mechanisms of acquired resistance to macrolides have been shown to be due to mutations in the 23S rRNA gene. Emergence and widespread dissemination of clinically significant high-level macrolide resistance in Asia and documentation of its occurrence to a lesser extent in several European countries and the United States during the past decade is worrisome since treatment options for children are limited. This article summarizes the current status of antimicrobial susceptibility testing, mechanisms of antimicrobial resistance, epidemiology of macrolide resistance and treatment alternatives for pediatric infections caused by M. pneumoniae.
Export Options
About this article
Cite this article as:
Waites B. Ken, Antimicrobial Susceptibilities and Treatment Options for Pediatric Mycoplasma pneumoniae Infections - Does Macrolide Resistance Matter?, Current Pediatric Reviews 2013; 9 (4) . https://dx.doi.org/10.2174/157339630904131223104312
DOI https://dx.doi.org/10.2174/157339630904131223104312 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Current Cardiology Reviews Henoch Schonlein Purpura in Childhood
Current Pediatric Reviews Recent Advances in Antiarrhythmic Drug Treatment of Atrial Fibrillation
Recent Patents on Cardiovascular Drug Discovery Drug Induced Cutaneous Manifestations due to Treatment of Gastrointestinal Disorders
Current Drug Metabolism Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design Effects of Tea Catechins on Inflammation-Related Cardiovascular Diseases
Current Immunology Reviews (Discontinued) Clinical Vignettes: Integrated Care of Cancer Patients by Oncologists and Cardiologists
Current Cardiology Reviews Polysaccharide Production in Pilot Scale Bioreactor Cultivations of Neisseria meningitidis Serogroup C
Current Biochemical Engineering (Discontinued) Pharmacological Therapy of Pericardial Diseases
Current Pharmaceutical Design Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity
Current Medicinal Chemistry Cardiovascular Involvement in Pediatric Systemic Autoimmune Diseases: The Emerging Role of Noninvasive Cardiovascular Imaging
Inflammation & Allergy - Drug Targets (Discontinued) New Viral Infection COVID-19: Current Status, Challenges and Possible Treatments
Letters in Drug Design & Discovery The Management of Thymoma - A Review of the Status Quo with Practical Treatment Recommendations
Current Respiratory Medicine Reviews Novel and Emerging Drugs for Systemic Lupus Erythematosus: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Association of Viruses in the Development of Cardiovascular Diseases
Current Pharmaceutical Design Diagnosis of Systemic Lupus Erythematosus in an Unusual Presentation: What a Primary Care Physician Should Know
Current Rheumatology Reviews Immune Therapy for Infectious Diseases at the Dawn of the 21st Century: the Past, Present and Future Role of Antibody Therapy, Therapeutic Vaccination and Biological Response Modifiers
Current Pharmaceutical Design Mixed Connective Tissue Disease (MCTD) and Undifferentiated Connective Tissue Disease (UCTD)
Current Rheumatology Reviews Perioperative Considerations in Rheumatoid Arthritis Patients
Current Rheumatology Reviews Bisphenol A as a Factor in the Mosaic of Autoimmunity
Endocrine, Metabolic & Immune Disorders - Drug Targets